Smoke Free Sweden: Oral Nicotine Pouches Are Game-changer for Women in Sweden's Smoke-free Success
STRASBOURG, France — New research from Smoke Free Sweden reveals oral nicotine pouches are a game-changer in Sweden's path to becoming the world's first smoke-free nation – and are driving unprecedented success among women.
Article content
The report, Power in a Pouch
Article content
, launched today in Strasbourg, shows pouches have been a decisive catalyst in Sweden's public health success – especially for women, who are quitting smoking faster and more effectively than ever.
Article content
Since their introduction in 2016, tobacco-free pouches have:
Article content
Helped to accelerate the decline in smoking for both genders, with a nearly 200% rise in quit rates among women.
Outperformed all other quit aids; women ranked pouches nearly three times higher than vapes and 56% higher than gum.
Been identified by the research as the preferred quit aid for all ex-smokers for being clean, socially considerate and stigma-free.
Driven a 49% drop in smoking among women, who historically quit at lower rates than men.
Article content
'The evidence is crystal clear: nicotine pouches are the most effective way to help smokers – especially women – quit,' said report co-author Dr. Marewa Glover, a behavioural scientist from New Zealand.
Article content
'Health data and women's testimonials show pouches are safe, socially acceptable, and fit modern lifestyles. They're pragmatic, effective, and our best hope for a smoke-free future.'
Article content
Sweden's harm reduction strategy stands in contrast to restrictive approaches elsewhere. Rather than banning safer products, Sweden embraced them – recognising they are far less harmful than cigarettes.
Article content
Sweden's smoking rate is now 5.3%, just above the 5% smoke-free benchmark. Male lung cancer deaths are 61% below the EU average; total cancer deaths, 34% lower.
Article content
Report co-author Dr. Delon Human warned that excessive regulation could jeopardise these gains, especially for women.
Article content
'Misguided bans are blocking access to products that save lives,' said Dr. Human, leader of Smoke Free Sweden and former Secretary-General of the World Medical Association.
Article content
'That's not just bad policy – it's a public health disaster. Women deserve access to the quit aid that works best.'
Article content
Article content
Article content
Article content
Article content
Article content
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CBC
21 minutes ago
- CBC
Trevor Arnason confirmed as Ottawa's top doctor
Dr. Trevor Arnason has been named Ottawa Public Health's (OPH) new medical officer of health, the city announced Wednesday during a meeting of city council. Arnason has been in the job in an interim capacity since February when Dr. Vera Etches left to become president and CEO of CHEO, eastern Ontario's children's hospital in Ottawa. Etches served as the city's top doctor through the COVID-19 pandemic, and her frequent public updates during that period made her a household name. Arnason joined OPH in 2019 as an associate medical officer of health, becoming deputy medical officer of health in May 2024, according to the city. Before joining OPH, he was the regional medical officer of health in Halifax. He served as the lead medical consultant for the city's COVID-19 vaccine distribution task force and was responsible for immunization programs, among other portfolios. Arnason was born and raised in Ottawa, completing his undergraduate and graduate degrees at the University of Ottawa before getting his doctorate at the University of Toronto. He certified in public health, preventative medicine and family medicine during his residency. He is also an adjunct professor at the University of Ottawa's Faculty of Medicine and served as program director for its public health and preventive medicine residency program from 2021 to 2024.


CTV News
an hour ago
- CTV News
Dr. Trevor Arnason named Ottawa's new medical officer of health
Dr. Trevor Arnason speaks to CTV News Ottawa. May 1, 2025. Arnason has been appointed as the new medical officer of health for the City of Ottawa. (Shaun Vardon/CTV News Ottawa) Ottawa City Council has approved the appointment of Dr. Trevor Arnason as the city's new medical officer of health. Arnason has been serving as the interim medical officer of health since Feb. 1, after Dr. Vera Etches left Ottawa Public Health earlier this year to become the new president and CEO of CHEO. Arnason served as deputy medical officer of health in Ottawa since May 2024 and associate medical officer of health (AMOH) since 2019. 'As AMOH, he was the physician responsible for immunization programs and served as the lead medical consultant for the City of Ottawa's COVID-19 Vaccine Distribution Taskforce. He has also been the AMOH responsible for portfolios in sexually transmitted and bloodborne Infections, chronic disease and injury prevention and mental health and substance use,' Ottawa Public Health says on its website. Prior to joining Ottawa Public Health, Arnason was the Regional Medical Officer of Health for Halifax, N.S. from 2016 to 2018. OPH says Arnason was born and raised in Ottawa and holds a Bachelor of Science (Hons) in Biology and a Master of Science in Epidemiology from the University of Ottawa and a Medical Doctorate from the University of Toronto. Arnason earned a salary of $270,912 in 2024 as deputy medical officer of health. Etches, in her final year as medical officer of health, earned $325,484, according to Ontario's Sunshine List.


Globe and Mail
2 hours ago
- Globe and Mail
Lantern Pharma (NASDAQ: LTRN) Secures EU Patent for AI-Designed Cancer Drug LP-284
Lantern Pharma (NASDAQ: LTRN) announced the European Patent Office has issued a notice of allowance for a composition of matter patent covering LP-284, a clinical-stage drug candidate for relapsed or refractory non-Hodgkin's lymphoma. The patent, expected to grant with exclusivity through 2039, adds to existing IP in the U.S. and Japan and supports global commercialization efforts. LP-284, developed using Lantern's RADR(R) AI platform, is in Phase 1 trials and holds Orphan Drug Designations for MCL and HGBL. The drug targets a $4 billion global market, and its rapid development timeline and cost efficiency bolster Lantern's strategic partnership potential. To view the full press release, visit About Lantern Pharma Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. The company's proprietary AI and machine learning platform, RADR(R), leverages over 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, Lantern has accelerated the development of its growing pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers. On average, Lantern's newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $2.5 million per program. NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company's newsroom at About BioMedWire BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today's market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text 'Biotech' to 888-902-4192 (U.S. Mobile Phones Only) For more information please visit Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: